NCT04636788

Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.

Detailed description

CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or other pancreatic lesions is not satisfying enough. Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably. By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.

Conditions

• Pancreas Adenocarcinoma

Interventions

Type	Name	Description
PROCEDURE	Venous sampling	venous sampling of 12ml

Timeline

• Start date: 2020-11-01
• Primary completion: 2021-11-01
• Completion: 2022-11-01
• First posted: 2020-11-19
• Last updated: 2020-11-19

Locations

1 site across 1 country: China